Hikma Pharmaceuticals PLC
HKMPYOTCHealthcare● Active
$39.08
$-0.19(-0.47%)
Market Cap$4.3B
P/E Ratio—
52W High$56.91
52W Low$31.8
Hikma Pharmaceuticals PLC (HKMPY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HKMPY · earnings · updated Jun 10, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 24, 2026EPS Actual
$1.48
Revenue
$1.68B
Est. $1.68B · +0.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 24, 2026
After Market Close
HKMPY reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 24, 2026 | — | $1.48 | — | $1.68B | $1.68B | +0.0% |
| — Q3 FY2025 | Aug 7, 2025 | — | $2.14 | — | $1.66B | — | — |
| — Q1 FY2025 | Feb 26, 2025 | — | $0.59 | — | $1.54B | — | — |
| — Q3 FY2024 | Aug 8, 2024 | — | $1.01 | — | $1.57B | — | — |
| — Q2 FY2024 | Apr 25, 2024 | — | $0.52 | — | $1.44B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $1.18 | — | $1.43B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.14 | — | $1.37B | — | — |
| — Q2 FY2022 | Jun 30, 2022 | — | $1.52 | — | $1.21B | — | — |
Q1 FY2026
Feb 24, 2026
EPS Actual
$1.48
EPS Est.
—
EPS Surpr.
—
Revenue
$1.68B
Q3 FY2025
Aug 7, 2025
EPS Actual
$2.14
EPS Est.
—
EPS Surpr.
—
Revenue
$1.66B
Q1 FY2025
Feb 26, 2025
EPS Actual
$0.59
EPS Est.
—
EPS Surpr.
—
Revenue
$1.54B
Q3 FY2024
Aug 8, 2024
EPS Actual
$1.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.57B
Q2 FY2024
Apr 25, 2024
EPS Actual
$0.52
EPS Est.
—
EPS Surpr.
—
Revenue
$1.44B
Q2 FY2023
Jun 30, 2023
EPS Actual
$1.18
EPS Est.
—
EPS Surpr.
—
Revenue
$1.43B
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
$1.37B
Q2 FY2022
Jun 30, 2022
EPS Actual
$1.52
EPS Est.
—
EPS Surpr.
—
Revenue
$1.21B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
| Q3 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
| Q2 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 24, 2026 | — | $43.75 | $44.62 | +1.99% |
| — Q3 FY2025 | Aug 7, 2025 | — | $51.72 | $47.56 | -8.04% |
| — Q1 FY2025 | Feb 26, 2025 | — | $58.00 | $54.80 | -5.52% |
| — Q3 FY2024 | Aug 8, 2024 | — | $47.84 | $50.70 | +5.98% |
| — Q2 FY2024 | Apr 25, 2024 | — | $46.50 | $46.50 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $45.94 | $45.94 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $36.95 | $39.35 | +6.50% |
| — Q2 FY2022 | Jun 30, 2022 | — | $40.10 | $41.11 | +2.52% |
Q1 FY2026+1.99%
Report Date
Feb 24, 2026
EPS Beat/Miss
—
Price Before
$43.75
Price After
$44.62
Q3 FY2025-8.04%
Report Date
Aug 7, 2025
EPS Beat/Miss
—
Price Before
$51.72
Price After
$47.56
Q1 FY2025-5.52%
Report Date
Feb 26, 2025
EPS Beat/Miss
—
Price Before
$58.00
Price After
$54.80
Q3 FY2024+5.98%
Report Date
Aug 8, 2024
EPS Beat/Miss
—
Price Before
$47.84
Price After
$50.70
Q2 FY2024+0.00%
Report Date
Apr 25, 2024
EPS Beat/Miss
—
Price Before
$46.50
Price After
$46.50
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$45.94
Price After
$45.94
Q4 FY2022+6.50%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$36.95
Price After
$39.35
Q2 FY2022+2.52%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$40.10
Price After
$41.11
Beat Rate0 / 8 quarters
Largest Move-8.04% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HKMPY ends December
Hikma Pharmaceuticals PLC (HKMPY) most recently reported earnings on February 24, 2026 for Q1 FY2026, posting EPS of $1.48 (in line with the analyst consensus of —).
Each quarter, investors track HKMPY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HKMPY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HKMPY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HKMPY earnings · 4 questionsHikma Pharmaceuticals PLC's next earnings report is expected around TBD. HKMPY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HKMPY historically reports after market close (AMC).
HKMPY earnings datewhen is HKMPY earningsHKMPY next earnings datewhen does HKMPY report earningsHKMPY earnings calendar
▸ Source: FMP · Hikma Pharmaceuticals PLC SEC filings · US GAAP · Hikma Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026